TickerTalks
Browse all tickers →
TickerTalks›$KLRA
KLKLRA

Kailera Therapeutics, Inc.

$KLRA·$2.4B·Biotechnology·Healthcare
$16.78-2.3%1Y-32.8%
Mentions · last 7 days
2026-08-16: 5 posts2026-08-17: 3 posts2026-08-18: 4 posts2026-08-19: 1 posts2026-08-20: 0 posts2026-08-21: 7 posts2026-08-22: 2 posts22+25%
Price updated 7m ago·X counts updated 2d ago
KLKLRA
$KLRAKailera Therapeutics, Inc.
$16.78-2.28%22 posts+25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $KLRA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-20

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Second-wave obesity biotech — post-IPO cash-and-catalyst play in a hot space, no revenue and no near-term event to trigger it.

Kailera Therapeutics is a clinical-stage obesity biotech developing next-generation GLP-1 and multi-receptor agonists — the 'second-wave' contenders behind Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. It IPO'd in 2024 and is now in the middle of Phase 2 data generation for its lead assets.

  • The pipeline is in the class the market wants: lead asset KAI-1729 is an oral GLP-1/GIP dual agonist targeting the same tirzepatide-adjacent mechanism — if the Phase 2 dose-escalation data (H2 2026-H1 2027 window) shows competitive weight-loss efficacy with a clean safety profile, this is the kind of asset big-pharma pays a premium to add to a wobbling obesity pipeline.
  • The financials are pre-revenue with a substantial burn: Q1 EPS at minus $0.67 and free cash flow at minus $68M — the cash pile from the recent capital raises is enough for about six quarters, so the pipeline data has to arrive before the next dilutive raise cycle to avoid a repricing.
  • The setup is currently coiling on volume: volume 4.4x the 30-day average on the recent price action suggests positioning is building — likely tied to the next Phase 2 update, which the market is anticipating without a fully public date.

Trajectory is coiling ahead of the next Phase 2 data readout; a positive Phase 2 with tirzepatide-competitive weight-loss efficacy re-rates the stock materially higher (2-4x moves are typical in this space), a safety signal or muted efficacy sends this into a downward funding-and-dilution cycle.

What to watch: Next Phase 2 KAI-1729 dose-escalation readout (H2 2026-H1 2027 window) — positive tirzepatide-competitive efficacy with clean safety re-rates the stock materially higher; a safety signal or muted efficacy triggers the funding-and-dilution cycle.

binary catalyst pendingno sentimentno revenue

Read the AI verdict + X sentiment for $KLRA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing injectable and oral gut-hormone receptor agonists targeting obesity and associated metabolic disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KLRA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $KLRA

Partial — Clinical-stage biotech developing injectable and oral gut-hormone receptor agonists targeting obesity and associated metabolic disorders; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-16.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-24.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
41.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-1.09$-0.90-21.6%
Q1 2026May 26, 2026$-3650.00$-0.78-470867.7%

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.67$-68.3M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$3.61-$4.26 – -$2.940
FY27$0$0 – $0-$3.84-$4.53 – -$2.800
FY28$0$0 – $0-$3.54-$5.51 – -$2.090
FY29$138.9M$138.9M – $138.9M-$4.01-$4.01 – -$4.015
FY30$522.1M$522.1M – $522.1M-$2.80-$2.80 – -$2.803

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyApr 20Investments, Lp Rtw10% owner500.0K sh$8.0MBuyApr 20Bain Capital Life Sciences Investors, Llc10% owner1.6M sh$25.0MBuyApr 20Andrew T. KaplanDirector8.4M sh$134.4MBuyApr 20Bain Capital Investors Llc10% owner8.4M sh$134.4MBuyApr 20Adam KoppelDirector1.6M sh$25.0M
+ 21 other (14 awards · 6 conversions · 1 exempt) in window

See when $KLRA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 83
AI summary

Initial Form 3 ownership statement filed by Kathleen Tregoning, a newly reportable officer or director at Kailera Therapeutics, Inc., disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying role. No operational implications for the company.

SC 13DActivist position (5%+)Apr 23SC 13D
SC 13DActivist position (5%+)Apr 23SC 13D
8-KCharter amendmentApr 208-K — Item 5.03: Charter amendment · Item 8.01: Other event
424B4Prospectus supplement (offering)Apr 17424B4
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
+ 31 other (17 3s · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore247wallst.com·6d ago2 GLP-1 Stocks That Could Double Your Money by 2031fool.com·8d agoKailera Reports Second Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.com·12d ago2 Beaten-Down GLP-1 Stocks to Buy on the Dipfool.com·41d agoKailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Winseekingalpha.com·47d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$CAPR$IOVA$NWBO$SLS$ABCL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport